Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

flatiron health

Onco_background

Oncology Today—December 8, 2025

This week’s oncology roundup covers major advances in targeted therapy,…

Artificial_Intelligence

AI in Healthcare and Digital Health Today—November 10, 2025

This week’s AI in Healthcare and Digital Health brief distills AI-driven…

by Timos Papagatsias

Artificial_Intelligence

AI in Healthcare and Digital Health Today—November 3, 2025

Here is your weekly brief that highlights the most relevant updates across AI…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Artificial Intelligence in Healthcare 2025 Review: From Pilot Tools to Operating Infrastructure
Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs

Tags

Alzheimer’s drug development Anavex Asundexian BIA bioinformatics Bispecific antibody therapy brain aging brain tumors Brenzavvy CAD cancer cancer neuroscience Cell and gene therapy pipeline Cereno Scientific Chiesi Rare Diseases Clinical immunology corporate venture capital Diffuse large B-cell lymphoma Elranatamab evinova Gene and cell therapy in hematology gene editing gene therapy approval hair loss treatments Headache disorders hematology international atherosclerosis society investor brief JPM 2026 Mild cognitive impairment Neoantigen vaccine NMPA China non viral vectors Oncology drug pipeline Pancreatic ductal adenocarcinoma Paroxysmal supraventricular tachycardia pharma pharmacogenomics Recessive dystrophic epidermolysis bullosa screening Sema4 Shanghai Mental Health Center SKYRIZI stiff person syndrome urticaria

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Artificial Intelligence in Healthcare 2025 Review: From Pilot Tools to Operating Infrastructure
Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs

TAGS

Alzheimer’s drug development Anavex Asundexian BIA bioinformatics Bispecific antibody therapy brain aging brain tumors Brenzavvy CAD cancer cancer neuroscience Cell and gene therapy pipeline Cereno Scientific Chiesi Rare Diseases Clinical immunology corporate venture capital Diffuse large B-cell lymphoma Elranatamab evinova Gene and cell therapy in hematology gene editing gene therapy approval hair loss treatments Headache disorders hematology international atherosclerosis society investor brief JPM 2026 Mild cognitive impairment Neoantigen vaccine NMPA China non viral vectors Oncology drug pipeline Pancreatic ductal adenocarcinoma Paroxysmal supraventricular tachycardia pharma pharmacogenomics Recessive dystrophic epidermolysis bullosa screening Sema4 Shanghai Mental Health Center SKYRIZI stiff person syndrome urticaria

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy